These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 35450837)

  • 61. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
    Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R
    J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.
    Kotani D; Oki E; Nakamura Y; Yukami H; Mishima S; Bando H; Shirasu H; Yamazaki K; Watanabe J; Kotaka M; Hirata K; Akazawa N; Kataoka K; Sharma S; Aushev VN; Aleshin A; Misumi T; Taniguchi H; Takemasa I; Kato T; Mori M; Yoshino T
    Nat Med; 2023 Jan; 29(1):127-134. PubMed ID: 36646802
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical utility of circulating tumor DNA for colorectal cancer.
    Osumi H; Shinozaki E; Yamaguchi K; Zembutsu H
    Cancer Sci; 2019 Apr; 110(4):1148-1155. PubMed ID: 30742729
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    Lipsyc-Sharf M; de Bruin EC; Santos K; McEwen R; Stetson D; Patel A; Kirkner GJ; Hughes ME; Tolaney SM; Partridge AH; Krop IE; Knape C; Feger U; Marsico G; Howarth K; Winer EP; Lin NU; Parsons HA
    J Clin Oncol; 2022 Aug; 40(22):2408-2419. PubMed ID: 35658506
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.
    Symonds EL; Pedersen SK; Yeo B; Al Naji H; Byrne SE; Roy A; Young GP
    Mol Oncol; 2022 May; 16(10):2031-2041. PubMed ID: 35000264
    [TBL] [Abstract][Full Text] [Related]  

  • 67. ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?
    Puccini A; Martelli V; Pastorino A; Sciallero S; Sobrero A
    Curr Treat Options Oncol; 2023 Feb; 24(2):76-92. PubMed ID: 36656505
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer.
    Mauri G; Vitiello PP; Sogari A; Crisafulli G; Sartore-Bianchi A; Marsoni S; Siena S; Bardelli A
    Br J Cancer; 2022 Aug; 127(3):394-407. PubMed ID: 35264786
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CtDNA's prognostic value in patients with early-stage colorectal cancer after surgery: A meta-analysis and systematic review.
    Fan X; Zhang J; Lu D
    Medicine (Baltimore); 2023 Feb; 102(6):e32939. PubMed ID: 36820557
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The role of circulating tumor DNA in evaluating minimal residual disease in luminal gastrointestinal malignancies.
    Ueberroth BE; Jones JC; Bekaii-Saab T
    Clin Adv Hematol Oncol; 2022 Jul; 20(7):444-455. PubMed ID: 35802877
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma.
    De Simoni E; Spagnolo F; Gandini S; Gaeta A; Rizzetto G; Molinelli E; Simonetti O; Offidani A; Queirolo P
    Cancer Treat Rev; 2024 Sep; 129():102788. PubMed ID: 38908229
    [TBL] [Abstract][Full Text] [Related]  

  • 72. New Insights into Adjuvant Therapy for Localized Colon Cancer.
    González NS; Ros Montaña FJ; Illescas DG; Argota IB; Ballabrera FS; Élez Fernández ME
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):507-520. PubMed ID: 35577707
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study.
    Li Y; Mo S; Zhang L; Ma X; Hu X; Huang D; Lu B; Luo C; Peng H; Cai S; Sheng W; Peng J
    Eur J Cancer; 2022 Jul; 169():198-209. PubMed ID: 35636041
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer.
    Boysen AK; Pallisgaard N; Andersen CSA; Spindler KG
    Acta Oncol; 2020 Dec; 59(12):1424-1429. PubMed ID: 32790489
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
    Filis P; Kyrochristos I; Korakaki E; Baltagiannis EG; Thanos D; Roukos DH
    Drug Discov Today; 2023 Apr; 28(4):103540. PubMed ID: 36822363
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.
    Wong R; Tie J; Lee M; Cohen J; Wang Y; Li L; Ma S; Christie M; Kosmider S; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Int J Cancer; 2019 Jul; 145(2):540-547. PubMed ID: 30628066
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges.
    Wen X; Coradduzza D; Shen J; Scanu AM; Muroni MR; Massidda M; Rallo V; Carru C; Angius A; De Miglio MR
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893604
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer.
    Zhou H; Zhu L; Song J; Wang G; Li P; Li W; Luo P; Sun X; Wu J; Liu Y; Zhu S; Zhang Y
    Mol Cancer; 2022 Mar; 21(1):86. PubMed ID: 35337361
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
    Loupakis F; Sharma S; Derouazi M; Murgioni S; Biason P; Rizzato MD; Rasola C; Renner D; Shchegrova S; Koyen Malashevich A; Malhotra M; Sethi H; Zimmermann BG; Aleshin A; Moshkevich S; Billings PR; Sedgwick JD; Schirripa M; Munari G; Cillo U; Pilati P; Dei Tos AP; Zagonel V; Lonardi S; Fassan M
    JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34327297
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
    Li FQ; Cui JW
    Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.